Table 2 Top mutations in modulating drug response among individual cancers
From: Predicting drug response of tumors from integrated genomic profiles by deep neural networks
Cancer | Gene | Mutation rate | Num. modulated drugs | Num. sensitive drugs | Num. resistant drugs |
|---|---|---|---|---|---|
LUAD | TP53 | 46.1% | 235 | 0 | 235 |
LUSC | TP53 | 75.1% | 228 | 0 | 228 |
STAD | TP53 | 43.3% | 224 | 0 | 224 |
HNSC | TP53 | 66.1% | 207 | 0 | 207 |
COAD | TP53 | 55.7% | 197 | 0 | 197 |
LIHC | TP53 | 27.0% | 194 | 1 | 193 |
BRCA | TP53 | 32.2% | 182 | 7 | 175 |
LGG | IDH1 | 77.3% | 159 | 138 | 21 |
PRAD | TP53 | 10.8% | 146 | 1 | 145 |
KIRC | PBRM1 | 38.0% | 142 | 3 | 139 |